Department of Gastroenterology, Changhai Hospital.
Outpatient Department of Changhai Hospital, Naval Medical University, Shanghai, China.
J Clin Gastroenterol. 2021 Sep 1;55(8):652-660. doi: 10.1097/MCG.0000000000001539.
The therapeutic efficacy of metal stents (MSs) for pancreatic fluid collections (PFCs) is invariably controversial. Here, we conducted a meta-analysis to summarize the results of efficacy of MSs and plastic stents (PSs) in PFC drainage.
We performed a literature search of PubMed/MEDLINE, EMBASE, and COCHRANE for all of the published studies regarding the use of MSs and PSs for endoscopic transmural drainage of PFCs from January, 1 2015 to June 1, 2020. We extracted data from 9 studies (1359 patients) that met the inclusion criteria. The main outcome measures were the rates of treatment success, including technique success and clinical success (CS), adverse events, recurrence, procedure time, and length of hospital stay (LOS).
There was no difference in overall technique success between patients treated with MSs and PSs for PFCs. However, MSs showed a higher CS rate 92% versus 82% (P<0.01) and a lower overall adverse event rate 20% versus 31% (P<0.01) than PSs. The recurrence rate of PFCs using MSs also had significant advantages over PSs 3% versus 10% (P<0.01) and MSs needed a shorter procedure time than PSs (26.73 vs. 45.40 min, P<0.01). In comparing direct endoscopic necrosectomy use and LOS, there was no difference between MSs and PSs.
Bringing together the results of the current study, endoscopic ultrasound-guided drainage of PFCs using MSs may be superior to PSs in terms of CS, adverse events rates and recurrence rate, with similar LOS and direct endoscopic necrosectomy use.
金属支架(MS)治疗胰腺液体积聚(PFC)的疗效一直存在争议。在此,我们进行了一项荟萃分析,以总结 MS 和塑料支架(PS)在 PFC 引流中的疗效结果。
我们对 2015 年 1 月至 2020 年 6 月期间发表的所有关于 MS 和 PS 用于内镜经壁引流 PFC 的研究进行了 PubMed/MEDLINE、EMBASE 和 Cochrane 文献检索。我们从符合纳入标准的 9 项研究(1359 例患者)中提取数据。主要观察指标为治疗成功率,包括技术成功率和临床成功率(CS)、不良事件、复发、操作时间和住院时间(LOS)。
MS 和 PS 治疗 PFC 的总体技术成功率无差异。然而,MS 的 CS 率(92%比 82%,P<0.01)和总体不良事件率(20%比 31%,P<0.01)均高于 PS。MS 治疗 PFC 的复发率也明显优于 PS(3%比 10%,P<0.01),且操作时间短于 PS(26.73 比 45.40 分钟,P<0.01)。在比较直接内镜下坏死组织清除术的使用和 LOS 时,MS 和 PS 之间无差异。
综合本研究结果,与 PS 相比,MS 经内镜超声引导引流 PFC 可能在 CS、不良事件发生率和复发率方面具有优势,而 LOS 和直接内镜下坏死组织清除术的使用无差异。